profit from every $100 of sales.
$0$100
Spok Holdings
$11.67+0.43% today
-15.6% in 1 year
1-year low $10.111-year high $13.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $15.38 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Spok Holdings sold, what it kept, and what it did with the cash.
Sales went from $135 million in 2022 to $140 million in 2025, with $15.9 million of profit last year.
SalesProfit
Spok Holdings handed back more cash to shareholders than it generated last year.
$27M
Free cash flow 2025$25M
Bought back its own shares$3M
Paid as dividends$27M
Cash vs. debt$25M vs. $7M
Spok Holdings vs. similar companies
Spok Holdings grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Spok Holdings | 15.4× · Fair price | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Spok Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 135 | 139 | 138 | 140 | |
| 106 | 112 | 109 | 110 | |
| 8 | 22 | 20 | 20 | |
| 11 | 26 | 24 | 24 | |
| 22 | 16 | 15 | 16 | |
| 1.09 | 0.77 | 0.73 | 0.75 | |
| 79.0% | 80.5% | 79.1% | 78.7% | |
| 5.6% | 15.7% | 14.6% | 14.4% | |
| 16.2% | 11.3% | 10.9% | 11.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 244 | 228 | 217 | 206 |
| Cash | 36 | 32 | 29 | 25 |
| Total debt | 16 | 11 | 9 | 7 |
| Total liabilities | 73 | 64 | 62 | 60 |
| 171 | 164 | 155 | 146 | |
| 20 | 20 | 21 | 21 | |
| 3.2% | 9.8% | 9.7% | 10.4% | |
| 12.8% | 9.6% | 9.7% | 10.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6 | 26 | 29 | 29 | |
| 4 | 3 | 3 | 4 | |
| 3 | 23 | 26 | 25 | |
| Dividends paid | 25 | 26 | 26 | 27 |
| 1 | 1 | 2 | 3 | |
| 4 | 4 | 5 | 5 |
Valuation
- 15.4×
- 17.7×
- –
- 1.6×
- 1.7×
- 9.7×
- 9.6×
- 10.3%
- 6.5%
- 11.3%
Profitability
- 78.7%
- 14.4%
- 11.4%
- 15.7%
- 7.6%
- 5.7%
- 8.6%
- 6.5%
- 10.9%
- 9.1%
Growth
- +1.3%
- −11.7%
- −2.0%
- +20.1%
- +1.5%
Financial health
- -0.5×
- 0.04
- 3.2%
- –
- 1.09
- 1.09
- 0.70
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 963
Top 39%of 894
Top 22%of 632
Bottom 19%of 908
Top 8%of 991
What analysts expect
- Average price target
- $15.00
- Range
- $15.00 – $15.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.09 | 0.18 | −50.0% |
| Feb 25, 2026 | 0.14 | 0.18 | −22.2% |
| Oct 29, 2025 | 0.15 | 0.19 | −21.1% |
| Jul 30, 2025 | 0.22 | 0.18 | +22.2% |
| Apr 30, 2025 | 0.25 | 0.18 | +38.9% |
| Feb 26, 2025 | 0.18 | 0.20 | −10.0% |
| Oct 30, 2024 | 0.18 | 0.18 | +0.0% |
| Jul 24, 2024 | 0.17 | 0.19 | −10.5% |
11.3%of the share price, paid each year
On $1,000 invested$113a year at today's yield, before tax
+20.1%2020 to 2025
Raised–not every year
Paid per share, each year
$0.63 in 2015 → $1.25 in 2025
How safe it looks
171.6% of its profit
Room to growStretchedMore than it earns: 108.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
56No pass
Philip Fisher
52No pass
Peter Lynch
28No pass
Joel Greenblatt
43No pass
Charlie Munger
51No pass
Terry Smith
49No pass
Questions about Spok Holdings
Is Spok Holdings a good stock to buy?
A solid business at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Spok Holdings AI analysis
What does Spok Holdings do?
Spok Holdings, Inc., through its subsidiary, Spok, Inc., provides healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. It delivers clinical information to care teams when and where it matters to enhance patient outcomes. It is in Medical - Healthcare Information Services.
Does Spok Holdings pay a dividend?
Yes. At today's price the dividend is 11.3% a year, about 172% of its yearly profit. In 2025 it paid out $27.3 million in dividends.
Is Spok Holdings stock halal?
Yes. Spok Holdings passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Spok Holdings stock done over the past year?
Down 15.6% over the past twelve months, to $11.67. It traded between $10.11 and $13.90 and is 16.0% below its high.
Who are Spok Holdings's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Spok Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.